A hospital in Mechelen (in the province of Antwerp), is the first to start treatment with a possible Covid-19 medication for patients with respiratory problems.
The drug, named Sarconeos (BIO101) was developed by French biotech company Biophytis and will be tested in five centres in Belgium, France and the United States.
In a first testing phase, fifty patients will be administered the drug in several countries. A further 260 patients will be added later.
Related News
- New drug could mean breakthrough in coronavirus treatment
- Coronavirus: Dexaméthasone not for patients in early stages of the illness
"Covid-19 can have devastating effects on patients, especially those at risk of developing serious respiratory complications. There is a great need for more treatment options to address these,” said pneumologist Muriel Lins, doctor in AZ Sint-Maarten - the hospital in Mechelen. Lins is the coordinator of the test programme in Belgium.
“We are pleased to be the first site to treat patients with BIO101,” she said. “It demonstrates our commitment to advancing clinical research on COVID-19 and providing the best care to patients with severe respiratory manifestations.”
The Brussels Times
